Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE versus KENALOG 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE versus KENALOG 10.
HYDROCORTISONE vs KENALOG-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a glucocorticoid that binds to the glucocorticoid receptor (GR), leading to altered gene expression. This results in anti-inflammatory, immunosuppressive, anti-proliferative, and vasoconstrictive effects. It also modulates carbohydrate, protein, and lipid metabolism.
Triamcinolone acetonide is a synthetic corticosteroid with anti-inflammatory, immunosuppressive, and antiproliferative actions. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production (e.g., IL-1, IL-2, TNF-alpha). It also stabilizes lysosomal membranes and inhibits fibroblast proliferation.
Oral: 10-20 mg every 6-8 hours; IV/IM: 100-500 mg every 2-6 hours for acute conditions; typical maintenance: 20-240 mg/day divided every 8-12 hours.
Intra-articular, intrabursal, or soft tissue injection: 10-40 mg (0.25-1 mL of 10 mg/mL) for large joints; 10 mg (0.25 mL) for small joints; repeat every 3-4 weeks if needed. Intralesional: 10-40 mg (0.25-1 mL) per lesion; maximum 1 mL per injection site; repeat every 1-2 weeks.
None Documented
Clinical Note
moderateHydrocortisone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Gatifloxacin."
Clinical Note
moderateHydrocortisone + Rosoxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rosoxacin."
Clinical Note
moderateHydrocortisone + Levofloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin."
Clinical Note
moderateNone Documented
Terminal half-life: 1.5–2 hours (plasma). In tissues, biologic half-life is 8–12 hours due to intracellular activity. Half-life prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2–5 hours for triamcinolone acetonide. However, the duration of action is prolonged due to the crystalline suspension's slow dissolution from the injection site, resulting in a prolonged residence time and effects lasting weeks. The plasma half-life primarily reflects systemic clearance after absorption.
Renal: primarily as inactive metabolites (cortisone, tetrahydrocortisone) and unchanged drug (<1%). Biliary/fecal: minimal (<5%).
Primarily hepatic metabolism (~80%) followed by renal excretion of inactive metabolites (glucuronide and sulfate conjugates). Unchanged triamcinolone acetonide accounts for <5% of urinary recovery. Biliary/fecal excretion is minor.
Category D/X
Category C
Corticosteroid
Corticosteroid
Hydrocortisone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Trovafloxacin."